1. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. (15th October 2014) Authors: Élez, E.; Kocáková, I.; Höhler, T.; Martens, U. M.; Bokemeyer, C.; Van Cutsem, E.; Melichar, B.; Smakal, M.; Csőszi, T.; Topuzov, E.; Orlova, R.; Tjulandin, S.; Rivera, F.; Straub, J.; Bruns, R.; Quaratino, S.; Tabernero, J. Journal: Annals of oncology Issue: Volume 26:Number 1(2015:Jan.) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO's Start-Up Unit Analysis. (October 2022) Authors: Matres, A.; Carballo, N.; Bernabé, Y.; Martínez, A.; Silverio, A.; Depares, I.; Cidoncha, I.; Beltran, M.; Braña, I.; Élez, E.; Díez, M.; Muñoz, E.; Saura, C.; Oaknin, A.; Macarulla, T.; Carles, J.; Felip, E.; Tabernero, J.; Garralda, E.; Pérez-Pujol, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗